This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (68) Citing Articles via Google Scholar Google Scholar Articles by Capone, M. L. Articles by Patrignani, P. Search for Related Content PubMed PubMed Citation Articles by Capone, M. L. Articles by Patrignani, P. Related Collections Related Article

EXPEDITED REVIEWS

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

Marta L. Capone, PhD^_*,, Maria G. Sciulli, PhD^_*,, Stefania Tacconelli, PhD^_*,, Marilena Grana, MD^_*,, Emanuela Ricciotti, PharmD^_*,, Giulia Renda, MD^_*,, Patrizia Di Gregorio, MD, Gabriele Merciaro and Paola Patrignani, PhD^_*,,_*

^_* Department of Medicine and Center of Excellence on Aging, School of Medicine, "G. d’Annunzio" University, Chieti, Italy
"G. d’Annunzio" University Foundation, Ce.S.I., Chieti, Italy
SS Annunziata Hospital, Chieti, Italy.

Manuscript received October 22, 2004; revised manuscript received December 17, 2004, accepted January 4, 2005.

^_* Reprint requests and correspondence: Dr. Paola Patrignani, Dipartimento di Medicina e Scienze dell’Invecchiamento, Università "G. d’Annunzio," Via dei Vestini 31, 66013 Chieti, Italy. (Email: ppatrignani{at}unich.it).

OBJECTIVES: We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen.

BACKGROUND: The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease.

METHODS: The incubation of washed platelets with naproxen for 5 min before the addition of aspirin reduced the irreversible inhibition of thromboxane (TX)B₂ production by aspirin. The pharmacodynamic interaction between the two drugs was then investigated in four healthy volunteers who received aspirin (100 mg daily) for 6 days and then the combination of aspirin and naproxen for further 6 days: aspirin 2 h before naproxen (500 mg, twice-daily dosing). After 14 days of washout, naproxen was given 2 h before aspirin for further 6 days.

RESULTS: The inhibition of serum TXB₂ production (index of platelet cyclooxygenase [COX]-1 activity) and platelet aggregation ex vivo and urinary 11-dehydro-TXB₂ levels (index of TXB₂ biosynthesis in vivo) by aspirin alone (99 ± 0.2%, 95 ± 0.6%, and 81 ± 4%, respectively) was not significantly altered by the co-administration of naproxen, given either 2 h after aspirin or in reverse order. In a second study, the concurrent administration of a single dose of aspirin and naproxen did not affect platelet TXB₂ production and aggregation at 1 h after dosing, when aspirin alone causes maximal inhibitory effect. Moreover, the rapid recovery of platelet COX-1 activity and function supports the occurrence of a pharmacodynamic interaction between naproxen and aspirin.

CONCLUSIONS: Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and function. This pharmacodynamic interaction might undermine the sustained inhibition of platelet COX-1 that is necessary for aspirin’s cardioprotective effects.

Abbreviations and Acronyms   AA = arachidonic acid   BID = twice-daily dosing   CI = confidence interval   COX = cyclooxygenase   IC50 = concentrations required to inhibit 50% of enzyme activity   NANSAIDs = nonaspirin nonsteroidal anti-inflammatory drugs   NSAIDs = nonsteroidal anti-inflammatory drugs   PG = prostaglandin   TX = thromboxane

Related Article

The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain

Steven R. Steinhubl
J. Am. Coll. Cardiol. 2005 45: 1302-1303. [Full Text] [PDF]

This article has been cited by other articles:

				L. Di Francesco, L. Totani, M. Dovizio, A. Piccoli, A. Di Francesco, T. Salvatore, A. Pandolfi, V. Evangelista, R. A. Dercho, F. Seta, et al. Induction of Prostacyclin by Steady Laminar Shear Stress Suppresses Tumor Necrosis Factor-{alpha} Biosynthesis via Heme Oxygenase-1 in Human Endothelial Cells Circ. Res., February 27, 2009; 104(4): 506 - 513. [Abstract] [Full Text] [PDF]

				F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance". J. Am. Coll. Cardiol., February 24, 2009; 53(8): 667 - 677. [Abstract] [Full Text] [PDF]

				L. A. Garcia Rodriguez, S. Tacconelli, and P. Patrignani Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1628 - 1636. [Abstract] [Full Text] [PDF]

				V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, September 1, 2008; 47(9): 1286 - 1298. [Abstract] [Full Text] [PDF]

				N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF]

				C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]

				J. I. Schwartz, A. L. Dallob, P. J. Larson, O. F. Laterza, J. Miller, J. Royalty, K. M. Snyder, D. L. Chappell, D. A. Hilliard, M. E. Flynn, et al. Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX-2 Versus COX-1 in Healthy Subjects J. Clin. Pharmacol., June 1, 2008; 48(6): 745 - 754. [Abstract] [Full Text] [PDF]

				P. Patrignani, M. L Capone, and S. Tacconelli NSAIDs and cardiovascular disease Heart, April 1, 2008; 94(4): 395 - 397. [Full Text] [PDF]

				G. A. FitzGerald Summary Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s51 - s52. [Full Text] [PDF]

				C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]

				F. M. Gengo, L. Rubin, M. Robson, M. Rainka, M. F. Gengo, D. E. Mager, and V. Bates Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis J. Clin. Pharmacol., January 1, 2008; 48(1): 117 - 122. [Abstract] [Full Text] [PDF]

				J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis Arch Intern Med, August 13, 2007; 167(15): 1593 - 1599. [Abstract] [Full Text] [PDF]

				M. L. Capone, S. Tacconelli, M. G. Sciulli, P. Anzellotti, L. Di Francesco, G. Merciaro, P. Di Gregorio, and P. Patrignani Human Pharmacology of Naproxen Sodium J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 453 - 460. [Abstract] [Full Text] [PDF]

				M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF]

				W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF]

				S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF]

				D. L. Bhatt NSAIDS and the risk of myocardial infarction: do they help or harm? Eur. Heart J., July 2, 2006; 27(14): 1635 - 1636. [Full Text] [PDF]

				C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., December 1, 2005; 353(22): 2373 - 2383. [Full Text] [PDF]

				M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF]

				S. R. Steinhubl The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1302 - 1303. [Full Text] [PDF]

				S. Fries and T. Grosser The Cardiovascular Pharmacology of COX-2 Inhibition Hematology, January 1, 2005; 2005(1): 445 - 451. [Abstract] [Full Text] [PDF]